<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:department>Cancer Studies and Molecular Medicine</gtr:department><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9A8719EF-1443-472E-A62B-A75637FCBCCC"><gtr:id>9A8719EF-1443-472E-A62B-A75637FCBCCC</gtr:id><gtr:firstName>Keith</gtr:firstName><gtr:otherNames>Rowland</gtr:otherNames><gtr:surname>Abrams</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E1E8D608-B9F9-4721-B634-1195C74BCE26"><gtr:id>E1E8D608-B9F9-4721-B634-1195C74BCE26</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:otherNames>Henry</gtr:otherNames><gtr:surname>Taylor</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/AA8CD29C-149A-44F5-8563-BA7A09420356"><gtr:id>AA8CD29C-149A-44F5-8563-BA7A09420356</gtr:id><gtr:firstName>Justin Chi</gtr:firstName><gtr:surname>Konje</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0801523"><gtr:id>9205DFD8-9522-441E-81A1-C82B4BC4032F</gtr:id><gtr:title>The endocannabinoid, anandamide as a biomarker of outcome in pregnancies complicated by threatened miscariage</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801523</gtr:grantReference><gtr:abstractText>Bleeding in early pregnancy is the most common emergency in obstetrics and gynaecology world wide. Although a significant number of the women would have already lost their pregnancies at the time of presentation, about 15-20% of all pregnant women present with this complication and will have live babies at the time of presetation (threatened miscarriage). Unfortunately 5-10% of these will subsequently miscarry spontaneously. There is currently neither a means of identifying the (90-95%) of cases that will proceed to having a live birth nor interventions to offer those destined to miscarry that will reduce this risk. As a result between 140,000 -160,000 women in the UK every year attend either their General Practitioners or Accident and Emergency Departments or Gynaecological Units repeatedly with this complication for reassurance. For the first time we have identified a molecule, called anandamide produced in the body, the measurement of whose levels in women presenting with a threatened miscarriage has been shown by our group in a small pilot study to predict approximately 94% of those who subsequently had live births and 100% of those who subsequently miscarried spontaneously. The research proposed here is seeking to confirm these pivotal pilot observations in a large population. If confirmed, this will eventually lead to the development of a bedside test which will be used to significantly reduce anxiety and repeated attendance as emergencies by these women and more importantly, will pave the way for us to investigate ways of altering the levels of this molecule to reduce the chances of miscarriage in those destined to lose their pregnancies because of high levels of this molecule. In addition, this test will radically change care pathways in various Recurrent Miscarriage Clinics nationally and internationally.</gtr:abstractText><gtr:technicalSummary>Human reproduction is notoriously inefficient with only 50-60% of all conceptions progressing beyond 20 weeks. Of the pregnancies that are lost, 75% represent failure of implantation with most of this occurring before clinical confirmation of pregnancy. Approximately 15-20% of ultrasound scan confirmed pregnancies present with threatened miscarriage and 5-10% of these subsequently end in a spontaneous miscarriage. In the UK in 2003, this equated to 139,120 out of 695,600 pregnancies. Threatened miscarriage is the commonest reason for General Practitioner emergency gynaecological referred in the UK. Although a very common emergency, there is currently no reliable test to predict which of the pregnancies will subsequently spontaneously miscarry. Consequently, the women end up having repeated visits to GPs and emergency units for ultrasound scans. For those destined to miscarry, the course of this process cannot unfortunately be modified. The endocannabinoid system has been shown to be the key cytokine-hormone network involved in the regulation of gametogenesis, oviductal transport, embryo development, implantation and maintenance of early pregnancy. This research proposes to measure in a larger population anandamide levels (which we have previously shown to have a 100% negative predictive value for subsequent spontaneous miscarriage) and fatty acid amide hydrolase activity in women presenting with a threatened miscarriage as biomarkers for pregnancy outcome. If confirmed, the results will eventually lead to the development of a reliable biomarker test for miscarriages and consequently open up the potential to modulate this system in those destined to fail.</gtr:technicalSummary><gtr:fund><gtr:end>2011-12-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>537987</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E881EB63-F551-4A22-827B-CF36909D81A0"><gtr:id>E881EB63-F551-4A22-827B-CF36909D81A0</gtr:id><gtr:title>Elevated anandamide and related N-acylethanolamine levels occur in the peripheral blood of women with ectopic pregnancy and are mirrored by changes in peripheral fatty acid amide hydrolase activity.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bc52973224881cf7331328d7a0cb985d"><gtr:id>bc52973224881cf7331328d7a0cb985d</gtr:id><gtr:otherNames>Gebeh AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4F12C743-FA15-4A4B-B1C8-24BCCEDF9F43"><gtr:id>4F12C743-FA15-4A4B-B1C8-24BCCEDF9F43</gtr:id><gtr:title>From Fertilisation to Implantation in Mammalian Pregnancy-Modulation of Early Human Reproduction by the Endocannabinoid System.</gtr:title><gtr:parentPublicationTitle>Pharmaceuticals (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b612a89cd57084c7e1dddfd4098878b1"><gtr:id>b612a89cd57084c7e1dddfd4098878b1</gtr:id><gtr:otherNames>Bambang KN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1424-8247</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1F8FB42E-A0CF-4CE2-85F3-FFE41FE03EA0"><gtr:id>1F8FB42E-A0CF-4CE2-85F3-FFE41FE03EA0</gtr:id><gtr:title>A bioplex analysis of cytokines and chemokines in first trimester maternal plasma to screen for predictors of miscarriage.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/474522e4b2e51667863a84c98ed41bea"><gtr:id>474522e4b2e51667863a84c98ed41bea</gtr:id><gtr:otherNames>Hannan NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A25757FA-1436-467F-B106-7D2681A4B696"><gtr:id>A25757FA-1436-467F-B106-7D2681A4B696</gtr:id><gtr:title>Endocannabinoid signaling at the periphery: 50 years after THC.</gtr:title><gtr:parentPublicationTitle>Trends in pharmacological sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/00d9ad307bce597218921ecf5140d48a"><gtr:id>00d9ad307bce597218921ecf5140d48a</gtr:id><gtr:otherNames>Maccarrone M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0165-6147</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F1B004C8-3A91-4EFE-87C3-233D396E1A97"><gtr:id>F1B004C8-3A91-4EFE-87C3-233D396E1A97</gtr:id><gtr:title>The manifold actions of endocannabinoids on female and male reproductive events</gtr:title><gtr:parentPublicationTitle>Frontiers in Bioscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0b1df23bd9b22137e5df26ac44599cc9"><gtr:id>0b1df23bd9b22137e5df26ac44599cc9</gtr:id><gtr:otherNames>Bari M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5BA25903-BDF5-4E23-A1C5-923165ED98BD"><gtr:id>5BA25903-BDF5-4E23-A1C5-923165ED98BD</gtr:id><gtr:title>Bradykinin-activated contractile signalling pathways in human myometrial cells are differentially regulated by arrestin proteins.</gtr:title><gtr:parentPublicationTitle>Molecular and cellular endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/157ecba92ce1345ecf87750fe4adb109"><gtr:id>157ecba92ce1345ecf87750fe4adb109</gtr:id><gtr:otherNames>Willets JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0303-7207</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/03991174-45BE-492D-AB1A-6DE23AF7ECB9"><gtr:id>03991174-45BE-492D-AB1A-6DE23AF7ECB9</gtr:id><gtr:title>Role of serum biomarkers in the prediction of outcome in women with threatened miscarriage: a systematic review and diagnostic accuracy meta-analysis.</gtr:title><gtr:parentPublicationTitle>Human reproduction update</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eb59a2244068d1a0e23b9644eb8dba46"><gtr:id>eb59a2244068d1a0e23b9644eb8dba46</gtr:id><gtr:otherNames>Pillai RN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1355-4786</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3A061311-67AE-440E-B947-02799C8FDED6"><gtr:id>3A061311-67AE-440E-B947-02799C8FDED6</gtr:id><gtr:title>Anandamide modulates human sperm motility: implications for men with asthenozoospermia and oligoasthenoteratozoospermia.</gtr:title><gtr:parentPublicationTitle>Human reproduction (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e0ad0cb46f7c7ed961fc1e7a0bbc893f"><gtr:id>e0ad0cb46f7c7ed961fc1e7a0bbc893f</gtr:id><gtr:otherNames>Amoako AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0268-1161</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/26B23558-2C5B-4983-AED8-4D8CAD4E8488"><gtr:id>26B23558-2C5B-4983-AED8-4D8CAD4E8488</gtr:id><gtr:title>Endocannabinoids and pregnancy.</gtr:title><gtr:parentPublicationTitle>Clinica chimica acta; international journal of clinical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8baa6007e55efb6996d3d2ad147693b3"><gtr:id>8baa6007e55efb6996d3d2ad147693b3</gtr:id><gtr:otherNames>Taylor AH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0009-8981</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7FA68F42-4028-412B-82B1-E79A9A2DE1E8"><gtr:id>7FA68F42-4028-412B-82B1-E79A9A2DE1E8</gtr:id><gtr:title>The effect of mifepristone (RU486) on the endocannabinoid system in human plasma and first-trimester trophoblast of women undergoing termination of pregnancy.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical endocrinology and metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8699750b21dd0b5d4cb8f2082b0febb5"><gtr:id>8699750b21dd0b5d4cb8f2082b0febb5</gtr:id><gtr:otherNames>Karasu T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-972X</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801523</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>FA7AA693-7EDD-4A7E-8CA3-6B5658FBF717</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Reproductive Health and Childbirth</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>